Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
← catalyst calendarNCT07286214 · readout in 1,020 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
14
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-12 | actual | When the study began enrolling |
| Primary completion | 2029-06-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-16 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Polymyalgia Rheumatica
Interventions
- Drug: Sarilumab — also filed as Kevzara®
- Drug: Sarilumab — also filed as Kevzara®
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFSustained remission at Week 52 (yes/no) in participants with early relapsing polymyalgia rheumatica (PMR) who received sarilumab 200 mg q2w with 52-week prednisone taper
measured at Week 52
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed